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Antigen-specific cytotoxic CD8+ T lymphocytes (CTLs) are
effective mediators of destructive anti-melanoma immu-
nity but primary CTL-sensitisation and establishment of
CTL-memory are dependent on the helper activity of anti-
gen-specific CD4+ T lymphocytes. Therefore, active immu-
notherapy of melanoma patients should ideally target
antigen-specific CD8+ and CD4+ T cells in order to achieve
effective anti-tumor CTL immunity. Identification of
tumor antigen epitopes is a prerequisite for specific T-cell
targeting in the course of vaccination and for vaccine eval-
uation. But in contrast to HLA-class I restricted peptide lig-
ands only a few HLA-class II-presented epitopes are
characterized. We used computer algorithms and HLA-
DRB1*0301 (HLA-DR3) transgenic mice to identify
epitopes derived from the differentiation antigen tyrosi-
nase-related protein-2 (TRP-2). Three potential HLA-DR3-
restricted epitopes were predicted from the TRP-2 protein
sequence, two of the corresponding synthetic peptides
exhibited HLA-DR3 binding capacity, but only one
sequence (Pep1) specifically activated CD4+ T cells in
HLA-DR3 transgenic mice after peptide immunization.
Processing of an epitope located in the Pep1 sequence
from the TRP-2 antigen was subsequently demonstrated
by TRP-2 protein immunization. Pep1-specific CD4+ T
cells could also be induced in vitro in human T cell cul-
tures obtained from the peripheral blood of normal HLA-
DRB1*0301 donors. Interestingly, in vivo sensitized Pep1-
specific T cells were also detectable in the peripheral
blood of HLA-DRB1*03 and HLA-DRB1*04 melanoma
patients verifying Pep1 as a target of spontaneous T cell
responses.
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